Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.

The aims of this study were to determine the clinical and histological characteristics of melanoma in transplant recipients, the mutation profile (BRAF, NRAS and c-KIT genes), and the immune tolerance of the tumour microenvironment by immunohistochemical study of the expression of indoleamine 2,3-dioxygenase (IDO), PD1, PD-L1, CD8 and FoxP3. The study population comprised patients who had undergone a renal transplant in Nantes University Hospital who developed post-transplantation melanoma. Twenty cases of melanoma out of 4,663 transplant recipients were studied. The results differed from the usual data with respect to melanoma site: 40% were located on the face and were of the malignant lentigo type. The mutation profile was concordant with that of the immunocompetent population. IDO was expressed in all the sections tested, while CD8, FoxP3, PD1 and PD-L1 were poorly expressed. This reflected a highly immunodepressed tumour environment, raising the question of the inductive role of IDO on tumour immune tolerance in patients presenting with long-term immunodepression.

[1]  P. Hwu,et al.  Targeting the indoleamine 2,3-dioxygenase pathway in cancer , 2015, Journal of Immunotherapy for Cancer.

[2]  D. Whiteman,et al.  Melanoma Incidence and Lethality Is Increased Following Solid Organ Transplantation. , 2015, The Journal of investigative dermatology.

[3]  A. Green,et al.  Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. , 2015, Acta dermato-venereologica.

[4]  S. Arron,et al.  Melanoma risk and survival among organ transplant recipients , 2015, The Journal of investigative dermatology.

[5]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[6]  D. Rimm,et al.  Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites , 2015, Clinical Cancer Research.

[7]  B. Dréno,et al.  Comparative analysis of BRAF, NRAS and c‐KIT mutation status between tumor tissues and autologous tumor cell‐lines of stage III/IV melanoma , 2015, Experimental dermatology.

[8]  B. Neyns,et al.  Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control? , 2014, The British journal of dermatology.

[9]  A. Webster,et al.  Survival After Cutaneous Melanoma in Kidney Transplant Recipients: A Population‐Based Matched Cohort Study , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  A. Chan,et al.  Systematic review of melanoma incidence and prognosis in solid organ transplant recipients , 2014, Transplantation research.

[11]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[12]  B. Dréno,et al.  Tissue Biomarkers in Melanoma Patients Treated with TIL , 2012, PloS one.

[13]  J. Lear,et al.  Melanoma in Organ Transplant Recipients: Incidence, Outcomes and Management Considerations , 2012, Journal of skin cancer.

[14]  B. Neyns,et al.  Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. , 2012, European journal of cancer.

[15]  G. Prendergast,et al.  Amino acid catabolism: a pivotal regulator of innate and adaptive immunity , 2012, Immunological reviews.

[16]  A. Weaver,et al.  Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. , 2011, Archives of dermatology.

[17]  Yohann Foucher,et al.  A clinical scoring system highly predictive of long-term kidney graft survival. , 2010, Kidney international.

[18]  D Ratner,et al.  Melanoma in Solid Organ Transplant Recipients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  Jean Kanitakis,et al.  BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. , 2010, European journal of dermatology : EJD.

[20]  C. L. Costantino,et al.  Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival , 2009, Cell cycle.

[21]  J. Bouwes Bavinck,et al.  Melanoma in Organ Transplant Recipients: Clinicopathological Features and Outcome in 100 Cases , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  Penny A. Johnson,et al.  Mechanisms of local immunosuppression in cutaneous melanoma , 2007, British Journal of Cancer.

[23]  C. Hollenbeak,et al.  Increased incidence of melanoma in renal transplantation recipients , 2005, Cancer.

[24]  M. Denis,et al.  Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. , 2004, Molecular and cellular probes.

[25]  B. Dréno,et al.  In vitro induction of matrix metalloproteinase‐2 and matrix metalloproteinase‐9 expression in keratinocytes by boron and manganese , 2004, Experimental dermatology.

[26]  E. Geissler,et al.  PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION , 2004, Transplantation.

[27]  W. Goggins,et al.  Cutaneous melanomas associated with nevi. , 2003, Archives of dermatology.

[28]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[29]  R. Hofmann-Wellenhof,et al.  Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis , 2002, Melanoma research.

[30]  O. Viklicky,et al.  Malignant melanoma in organ transplant recipients: incidence, outcomes, and management strategies: a review of literature , 2016, Dermatologic therapy.